BPN 14770

Drug Profile

BPN 14770

Alternative Names: BPN-14770

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tetra Discovery Partners
  • Class Antidementias
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Fragile X syndrome

Most Recent Events

  • 07 Nov 2017 Preclinical trials in Fragile X syndrome in USA (unspecified route)
  • 07 Nov 2017 Pharmacodynamics data from preclinical studies in Fragile X Syndrome released by Tetra Discovery Partners
  • 06 Nov 2017 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by Tetra Discovery Partners
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top